We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Data Analysis of the Cytokine Adsorption Treatment on Coronavirus Disease-19 (COVID-19) Patients With Respiratory Failure (CYTOAID)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04422626
Recruitment Status : Unknown
Verified June 2020 by University of Pecs.
Recruitment status was:  Not yet recruiting
First Posted : June 9, 2020
Last Update Posted : June 11, 2020
Sponsor:
Information provided by (Responsible Party):
University of Pecs

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Severe sepsis and septic shock are some of the leading causes of mortality in intensive care unit (ICU) admitted COVID-19 patients. The main cause of early mortality is the uncontrolled release of inflammatory mediators leading to cardiovascular failure. CytoSorb, a recently developed, highly biocompatible hemadsorption device has been tested, which can selectively remove inflammatory mediators from the circulation. This device is currently commercially available, and in Europe, it has been approved for clinical use. Based on experience to date, this adsorption technique may influence the immune function; removing inflammatory mediators from the blood may improve organ functions and even increase the chances of survival. CYTOAID is an observational, non-interventional study to assess the effectiveness of early cytokine adsorption therapy in critically ill patients who have been admitted to the ICU because of COVID-19 infection. Data on the applied therapy on COVID-19 patients in ICU will be collected and analyzed. The patient's examination and therapy will be applied according to the current regulations at the clinics and the current professional standards. The study does not require any additional examination or intervention.

Condition or disease
SARS-CoV-2 COVID-19

Detailed Description:

In the early phase of sepsis, the activation of innate immunity plays a significant role. Immune cells enhance the production of pro-inflammatory mediators. These pro-inflammatory mediators are responsible for the development of immune response and the intensification of the inflammatory processes. To counteract this, anti-inflammatory mediators limit and alleviate inflammation. Critically ill septic patients with higher levels of both anti- and proinflammatory mediators are at higher risk for death. The main cause for early mortality is the uncontrolled release of inflammatory mediators leading to cardiovascular failure, while in the late phase of the disease, secondary infections and the subsequent multiorgan failure dominate due to the exhaustion of the immune functions and the subsequent insufficient protective mechanisms. Therefore, it has been suggested that the outcomes of severe sepsis can be improved by attenuating the inflammatory processes. A recently developed, highly biocompatible hemadsorption device has been tested that can selectively remove inflammatory mediators from the circulation. This device is currently commercially available, and in Europe, it has been approved for clinical use. Based on experience to date, this adsorption technique may influence the immune function; removing inflammatory mediators from the blood may improve organ functions and even increase the chances of survival.

During the study, data will be collected exclusively; the application of CytoSorb therapy will be considered by the current physician always on an individual basis. Data will be recorded during hospitalization (using the documentations of the ICU) and immediately after discharge.

This study is suitable for recording every step of medical care from the diagnosis of SARS-CoV-2 infection. To investigate the biomarkers and the genetic background that potentially play a role in the infection, biological samples will be also collected - by already indicated interventions during standard care, i.e. without additional intervention.

This study aims to describe cytokine adsorption therapy (CytoSorb) in general and to detect its most important features. The study would also like to assess the safety and cost-effectiveness of the therapy, evaluate specific interventions required during the treatment, and to assess the outcomes of the disease. This study can provide important data and expand our knowledge about COVID-19 and its treatment, as well as improve the outcomes of the disease.

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 42 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Data Collection on the Application of Cytokine Adsorption Therapy on Patients With Acute Respiratory Failure Caused by COVID-19
Estimated Study Start Date : July 1, 2020
Estimated Primary Completion Date : July 1, 2022
Estimated Study Completion Date : December 1, 2022

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
Critically ill COVID-19 patients, who receive CytoSorb therapy
Patients in ICU due to critical COVID-19 infection, who receive early (within the first 24 hours, but no later than 48 hours after intubation) CytoSorb therapy on consultant's discretion.


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change in the partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) ratio after CytoSorb therapy [ Time Frame: 24 months ]
    Change in the PaO2/FiO2 ratio after CytoSorb therapy as compared to baseline


Secondary Outcome Measures :
  1. Change in inflammatory biomarker levels during treatment [ Time Frame: 24 months ]
    Change in white blood cell count and c-reactive protein levels during treatment compared to the baseline

  2. change in organ function [ Time Frame: 24 months ]
    measured by sequential organ failure assessment (SOFA/sub-SOFA) score during treatment assessed by the treating physician

  3. length of stay in ICU [ Time Frame: 24 months ]
    given in days, assessed by the treating physician

  4. length of hospital stay [ Time Frame: 24 months ]
    given in days, assessed by the treating physician

  5. Duration of mechanical ventilation [ Time Frame: 24 months ]
    given in days, assessed by the treating physician

  6. Duration of vasopressor therapy [ Time Frame: 24 months ]
    given in days, assessed by the treating physician

  7. Duration of renal replacement therapy [ Time Frame: 24 months ]
    given in days, assessed by the treating physician

  8. Occurrence of critical illness polyneuropathy and/or myopathy [ Time Frame: 24 months ]
    assessed by the treating physician

  9. need for extracorporeal membrane oxygenation (ECMO) [ Time Frame: 24 months ]
    Number of patients progressing to the need for ECMO assessed by the treating physician

  10. cost calculation [ Time Frame: 24 months ]
    The financial demand of the treatment of COVID-19 infection spent on each patient will be calculated by a healthcare economist after the trial is completed.

  11. device-related adverse and serious adverse events [ Time Frame: 24 months ]
    Number of patients with device-related adverse and serious adverse events assessed by the treating physician

  12. In-hospital mortality [ Time Frame: 24 months ]
    Number of patients, who died during their hospital stay, assessed by the treating physician


Biospecimen Retention:   Samples Without DNA
Three tubes (less than 25 ml) of blood and 2 ml of saliva will be collected to detect different antibodies, just in case if the physician already ordered blood test. Additional puncture won't be carried out.

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Probability Sample
Study Population
All adult patients admitted to ICUs requiring mechanical ventilation with proven COVID-19 infection and treated with CytoSorb.
Criteria

Inclusion Criteria:

  • Age >18 years
  • confirmed COVID-19 infection
  • ICU admission
  • Mechanical ventilation due to COVID-19 pulmonary complications
  • Moderate to severe acute respiratory distress syndrome (ARDS)
  • CytoSorb therapy indicated by the attending medical team preferably within the first 24 hours, but no later than 48 hours after intubation
  • Informed consent for data collection

Exclusion Criteria:

  • Unlikely survival for 24 hours according to the attending physician
  • Acute onset of hemato-oncological illness
  • Patient already on ECMO
  • Immunosuppression: on chronic systemic steroid therapy (>10 mg prednisolon/day); immunosuppressive agents (i.e.: methotrexate, azathioprine, cyclosporin, tacrolimus, cyclophosphamide)
  • Patients with transplanted vital organs
  • Thrombocytopenia (<20,000/uL)
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04422626


Contacts
Layout table for location contacts
Contact: Péter Hegyi, MD, PhD, Dsc +36703751031 hegyi2009@gmail.com
Contact: Zsolt Molnár, MD, PhD, Dsc zsoltmolna@gmail.com

Sponsors and Collaborators
University of Pecs
Investigators
Layout table for investigator information
Study Chair: Péter Hegyi, MD, PhD, DSc Insitute for Translational Medicine, University of Pécs, HU
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: University of Pecs
ClinicalTrials.gov Identifier: NCT04422626    
Other Study ID Numbers: 20802-5/2020/EÜIG
First Posted: June 9, 2020    Key Record Dates
Last Update Posted: June 11, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Pecs:
CytoSorb
COVID-19
acute respiratory failure
 cytokine
Intensive care unit
Sars-CoV-2
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Insufficiency
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
 Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Respiration Disorders